目的 采用亲和离心管法检测甲胎蛋白异质体（alpha Fetoprotein-L3，AFP-L3），分析甲胎蛋白异质体AFP-L3在诊断肝癌的临床应用价值。方法 选择150例临床检测甲胎蛋白AFP阳性者（≥20 ng/ml），使用亲和离心管方法检测甲胎蛋白异质体AFP-L3，研究检测甲胎蛋白异质体（AFP-L3）用于临床鉴别肝癌的作用。结果 以甲胎蛋白异质体AFP-L3≥10%作为诊断指标，对78例临床确诊为肝癌的患者甲胎蛋白异质体AFP-L3的诊断灵敏度是91.03%（71/78）；在72例临床诊断为其他肝脏疾病的患者甲胎蛋白异质体AFP-L3的诊断特异性达到95.83%（69/72）；甲胎蛋白异质体AFP-L3的符合率为93.33%［（71+69）/150］。结论 新型亲和离心柱法检测甲胎蛋白异质体AFP-L3对良、恶性肝病的鉴别诊断具有重要临床价值。
Abstract
Objective To explore the clinical significance of alpha-fetoprotein-L3%( AFP-L3) with centrifugal column method in the diagnosis of hepatocelluar carcinoma. Methods The serum samples of 150 patients with elevated AFP level (≥20 ng/ml) were detected by chemiluminescence immunoassay for AFP and centrifugal column method for AFP-L3，and the clinical value of AFP-L3 were studied in the differentiation diagnosis of hepatocelluar cancer. Results Taking AFP-L3≥10 ng/ml as the diagnositic criteria，the sensitivity of AFP-L3 was 91.03% （71/78）in 78 hepatocellular carcinoma patients and the specificity of AFP-L3 was 95.83%(69/72）in 72 other liver diseases patients. The diagnostic accuracy was 93.33%［（71+69）/150］. Conclusion Detection of AFP-L3 seemed be of clinical value in benign or malignant liver disease.
关键词
甲胎蛋白异质体 /
肝癌 /
亲和离心管法
Key words
alpha-fetoprotein isoforms /
hepatocelluar /
carcinoma /
centrifugal column method
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］ Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis c（A systematic review）［J］. Hepatology, 2002,36:84-92.
［2］ 陈灏珠. 实用内科学［M］. 13版.北京: 人民卫生出版社, 2009: 2108.
［3］ 贾志凌，王 莉，刘 畅，等.甲胎蛋白异质体对肝癌诊断的临床意义［J］.中国肿瘤，2010,19（10）:686-688.
［4］ Fed Regist. Classification of AFP-L3 immunological test systems［J］. Medical devices, immunology and microbiology devices, 2005, 70:57748-57750.
［5］ 徐正才, 郑晓燕, 徐春仙, 等 . 离心管法甲胎蛋白异质体检测的临床应用探讨 ［J］. 中国卫生检验杂志 , 2009,19(11): 2623-2624.
［6］ 马端叶，于丽梅，封建凯，等.甲胎蛋白异质体检测在肝癌诊断中的应用［J］.当代医学，2011,12（17）:113.
［7］ Richard K.S ,Lennox J, Fredric G, et al. Utility of Lens Cullinaris Agglutinin-Reactive Fraction of α-Fetoprotein and Des-Gamma-Carboxy Prothrombin, alone or in combination, as Biomarkers for Hepatocellular cellularcarcinoma［J］. Clinical Gastroenterology and Hepatology,2009,7(1):104-113.
［8］ Yasushi T, Masato I, Takeshi S, et al. Fucosylated fraction of Alpha-Fetoprotein a predictor of prognosis in patients with hepatocellular cacinoma after curative treatment［J］. Digestive disease and science,2010,55(7):2095-2101.
［9］ Giulia M, Maria G, Isabella P, et al. Serum marker of hepatocellular carcinoma［J］. Digestive disease and sciences,2010,55(10):2744-2755.
［10］ Masahiro K,Tetsuya H, Kenji I, et al. Highly sensitive AFP-L3 assay is useful for predicting recurrence of hepatocellular cacinoma after curative treatment pre-andpostoperatively［J］. Hepatology Research, 2011,41(11):1036-1045.
PDF(593 KB)
